Keros Therapeutics (KROS) shares new Phase 1 KER-065 data in 8-K

Rhea-AI Filing Summary

Keros Therapeutics, Inc. reported that it issued a press release on September 8, 2025 describing additional clinical data from its Phase 1 trial of KER-065 in healthy male volunteers. The company presented these data at the American Society of Bone and Mineral Research 2025 Annual Meeting held on September 6, 2025.

The Form 8-K notes that the press release is furnished as Exhibit 99.1 and is incorporated by reference, except for the quoted statements. No financial results or transaction details are included in this report, which focuses on the disclosure of new early-stage clinical information about KER-065.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001664710FALSE00016647102025-09-082025-09-080001664710us-gaap:CommonStockMember2025-09-082025-09-080001664710us-gaap:PreferredStockMember2025-09-082025-09-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2025

Keros Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39264

81-1173868

(state or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

1050 Waltham Street, Suite 302 Lexington, Massachusetts

02421

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 314-6297

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

KROS

The Nasdaq Stock Market LLC

Preferred Share Purchase Rights

N/A

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01    Other Events.

On September 8, 2025, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing that it presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male volunteers at the American Society of Bone and Mineral Research 2025 Annual Meeting on Saturday, September 6, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and, other than the quotes contained therein, is incorporated herein by reference.

Item 9.01     Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.						Description
99.1						Press Release dated September 8, 2025.
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KEROS THERAPEUTICS, INC.
By:						/s/ Jasbir Seehra
						Jasbir Seehra, Ph.D. Chief Executive Officer

Dated: September 8, 2025

FAQ

What did Keros Therapeutics (KROS) disclose in this 8-K filing?

Keros Therapeutics disclosed that it issued a press release on September 8, 2025 announcing additional clinical data from its Phase 1 trial of KER-065, which were presented at the American Society of Bone and Mineral Research 2025 Annual Meeting.

What is the focus of the new information from Keros Therapeutics (KROS)?

The new information relates to additional clinical data from a Phase 1 trial of KER-065 in healthy male volunteers, presented at a major bone and mineral research conference.

Does this Keros Therapeutics (KROS) 8-K include financial results or earnings data?

No, this 8-K centers on other events, specifically a clinical data presentation and related press release about KER-065, and does not provide financial results or earnings data.

Where can investors find the detailed KER-065 Phase 1 data mentioned by Keros Therapeutics (KROS)?

The detailed information is in the press release furnished as Exhibit 99.1 to the 8-K, which is incorporated by reference except for quotations contained in it.

What exhibits did Keros Therapeutics (KROS) attach to this 8-K filing?

Keros included Exhibit 99.1, the press release dated September 8, 2025, and Exhibit 104, the cover page interactive data file with Inline XBRL tags.

Who signed the Keros Therapeutics (KROS) 8-K related to KER-065 data?

The report was signed on behalf of Keros Therapeutics by Jasbir Seehra, Ph.D., Chief Executive Officer.